Symphogen, a Danish biotechnology company specializing in the research and development of monoclonal antibodies, becomes Servier’s center of excellence for antibodies, strengthening the Group’s pipeline in various therapeutic areas, including oncology.
Symphogen, now a subsidiary of Servier, keep its operational autonomy and continue to rely on its experienced employees.
As part of the acquisition, Christophe Thurieau, Executive Director of Servier Research Institute, has been appointed Chief Executive Officer of Symphogen and Karin Garre, former Chief Operating Officer of Symphogen, has been appointed General Manager of Symphogen. Martin Olin, former Chief Executive Officer of Symphogen, will act as an external consultant to support this transition.
Claude Bertrand, Executive Vice-President Research & Development at Servier, said: “The completion of this acquisition enables Servier to boost its antibody capabilities in oncology and in its other therapeutic areas. This efficient antibody discovery and research platform of Symphogen will strengthen our R&D capabilities and pipeline in line with our aim of making life-saving treatments available to a greater number of patients across the world.”
Founded in 2000 and based in Denmark, Symphogen is a biotech company that has developed an efficient discovery and research platform that can rapidly identify high quality monoclonal and bi-specific antibodies supported by early development capabilities with strong in vitro and in vivo capacities across oncology and immuno-oncology. Symphogen is organized as a combined project and line organization with various research, pre-clinical, CMC (Chemistry, Manufacturing and Control), clinical and regulatory departments.
As part of the acquisition by Servier, Symphogen becomes the antibody center of excellence of the Group as its platform can deliver antibodies with unique functionalities providing best or first in class potential.
In line with the values of Servier, Symphogen believes in the power of teamwork and is committed to developing innovations for the benefit of patients.
95 employees including 81% in R&D
6 years average seniority of the workforce
40% / 60% gender split between men and women